MINI REVIEW article
Front. Endocrinol.
Sec. Endocrinology of Aging
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1619516
This article is part of the Research TopicOvarian Aging: Pathophysiology and Recent Development of Maintaining Ovarian Reserve, Volume IVView all 12 articles
Ovarian Aging: Pathophysiology and Recent Developments in Maintaining Ovarian Reserve
Provisionally accepted
Mana Hirano
Takako OnoderaKazuki TakasakiYuko TakahashiTakayuki IchinoseHaruka NishidaHaruko Hiraike
Kazunori Nagasaka*- Teikyo University, Itabashi, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
According to the World Health Organization, infertility has emerged as a critical public health issue, affecting approximately 48 million couples and 186 million individuals worldwide. Ovarian agingdefined by the progressive depletion and functional deterioration of the primordial follicle poolaccounts for a major proportion of female-factor infertility and has profound socioeconomic consequences. It is characterized by a decline in follicle quantity and quality, which significantly influences infertility. This phenomenon is multifaceted, involving genetic predisposition, hormonal fluctuations, mitochondrial dysfunction, oxidative stress, and ovarian microenvironment alterations. This review explores the biological mechanisms of ovarian aging, evaluates current therapeutic advances, and identifies strategies to maintain ovarian function and prolong reproductive lifespan. Recent advancements-including antioxidant and mitochondria-targeted therapies, hormonal modulation, growth factor interventions (e.g., platelet-rich plasma), mitochondrial transfer, and in vitro follicle activation-show promise for maintaining ovarian reserve. Fertility preservation strategies, such as ovarian tissue cryopreservation and transplantation, and pharmacological inhibition of follicle depletion, have expanded therapeutic options. The development of personalized treatments, refined biomarkers, and integrative strategies combining antioxidants, hormonal therapies, and novel fertility preservation techniques is essential. Therefore, translational research utilizing animal models remains crucial for validating efficacy and safety prior to clinical application. Future research should prioritize validating these emerging therapies through larger clinical trials to ensure safe, effective, and practical translation into clinical practice, ultimately prolonging reproductive lifespan and enhancing quality of life for aging women.
Keywords: ovarian aging, ovarian reserve, Fertility Preservation, Follicle depletion, hormonal therapies, Menopause, Delayed parenthood, biomarker-driven
Received: 28 Apr 2025; Accepted: 11 Sep 2025.
Copyright: © 2025 Hirano, Onodera, Takasaki, Takahashi, Ichinose, Nishida, Hiraike and Nagasaka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kazunori Nagasaka, Teikyo University, Itabashi, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.